Rafet Başar - Concepedia

Author

Rafet Başar

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Basar, Rafet, R Basar, Rafet Basar, Rafet Başar

158

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Hospital Israelita Albert Einstein Universidade de São Paulo Baylor College of Medicine The University of Texas Health Science Center at Houston

About

Rafet Başar is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	19	4.4K
2	Health Sciences	1	1	17
3	Public Health	1	1	69
4	Allergy	1	1	35
5	Biostatistics	1	1	17

Rafet Başar

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
B cells and tertiary lymphoid structures promote immunotherapy response Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao, Nature Humoral ResponseImmunologyB CellsAutoimmunityHumoral Immunity	2020	2.5K
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Enli Liu, David Marín, Pinaki P. Banerjee, New England Journal of Medicine	2020	2K
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity E Liu, Yijiu Tong, Gianpietro Dotti, Leukemia Cell TherapyCancer ImmunosurveillanceImmunologyPotent Antitumor ActivityImmunologic Mechanism	2017	778
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial David Marín, Ye Li, Rafet Başar, Nature Medicine	2024	376
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells May Daher, Rafet Başar, Elif Gokdemir, Blood	2020	272
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells Hila Shaim, Mayra Shanley, Rafet Başar, Journal of Clinical Investigation Cell TherapyImmunologyImmune RegulationImmunoeditingImmunotherapeutics	2021	234
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape Ye Li, Rafet Başar, Guohui Wang, Nature Medicine Natural Killer CellsImmunologyTumor EscapeCell DeathImmune Checkpoint Inhibitor	2022	152
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies Lucila Nassif Kerbauy, Nancy D. Marín, Mecit Kaplan, Clinical Cancer Research	2021	147
Next-generation cell therapies: the emerging role of CAR-NK cells Rafet Başar, May Daher, Katayoun Rezvani Blood Advances Cell TherapyAdaptive Immune SystemImmunologyImmunoeditingCd4 T Cell Responses	2020	127
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway Kimie Kondo, Hila Shaim, Philip A. Thompson, Leukemia InflammationCytokineAutoimmune DiseaseImmune RegulationImmunology	2017	118

Page 1